ARGENX SE's ticker is ARGX and the CUSIP is 04016X101. A total of 137 filers reported holding ARGENX SE in Q2 2019. The put-call ratio across all filers is 2.14 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $1,195,000 | -88.4% | 4,064 | -89.6% | 0.03% | -92.3% |
| Q3 2020 | $10,282,000 | -44.1% | 39,168 | -52.1% | 0.35% | -47.5% |
| Q2 2020 | $18,402,000 | +27.8% | 81,704 | -25.3% | 0.66% | -14.3% |
| Q1 2020 | $14,403,000 | -40.2% | 109,338 | -27.2% | 0.78% | -30.0% |
| Q4 2019 | $24,102,000 | +39.4% | 150,148 | -1.1% | 1.11% | +16.5% |
| Q3 2019 | $17,296,000 | -15.2% | 151,770 | +5.3% | 0.95% | -5.6% |
| Q2 2019 | $20,403,000 | +12.4% | 144,106 | -0.9% | 1.01% | +3.4% |
| Q1 2019 | $18,150,000 | +3.8% | 145,386 | -20.1% | 0.98% | -21.3% |
| Q4 2018 | $17,489,000 | +27.1% | 182,040 | +0.4% | 1.24% | +66.1% |
| Q3 2018 | $13,756,000 | +74.0% | 181,379 | +90.1% | 0.75% | +56.7% |
| Q2 2018 | $7,906,000 | +108.7% | 95,419 | +102.6% | 0.48% | +73.7% |
| Q1 2018 | $3,789,000 | -28.1% | 47,100 | -43.5% | 0.27% | -33.8% |
| Q4 2017 | $5,267,000 | – | 83,418 | – | 0.41% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 39,370 | $14,917,000 | 13.60% |
| Tri Locum Partners LP | 82,735 | $31,347,000 | 12.84% |
| Avoro Capital Advisors LLC | 1,265,555 | $479,493,000 | 9.48% |
| Artal Group S.A. | 400,000 | $151,552,000 | 8.10% |
| Finepoint Capital LP | 52,800 | $20,005,000 | 6.92% |
| Paradigm Biocapital Advisors LP | 88,816 | $33,651,000 | 6.71% |
| Fairmount Funds Management LLC | 73,526 | $27,858,000 | 6.38% |
| DCF Advisers, LLC | 25,000 | $9,472,000 | 5.64% |
| Redmile Group, LLC | 385,818 | $146,179,000 | 5.58% |
| Eagle Health Investments LP | 60,300 | $22,846,000 | 5.33% |